|Day Low/High||16.84 / 17.55|
|52 Wk Low/High||2.65 / 23.91|
Market players are trying to decipher Fed Chair Powell's latest words.
Market players are more skeptical of the quick moves on U.S.-China trade news.
Poor trading action in Lyft will likely create some distrust of upcoming IPOs, and Uber in particular.
Valuation and all the other issues that are being discussed are secondary to the price action.
While there is some positive movement, it has not been sustained which makes trading quite tricky.
China negotiations resume today and the potential for weekend news is high.
So far there is no bounce in Kraft Heinz which is not a good sign.
It is the action in secondary stocks that is giving the action a much better feel.
This is the kind of reversal that happens in a bull market.
This stock can become much cheaper if there is a major cycle turn occurring.
The indices need to find support and we need some better pockets of strength.
Latest trial results appear to show the biotech has a super fish oil pill with potential to aid those with high triglycerides.
The market continues to be flat as we enter the last hour of the trading week. It looks like the SCOTUS nomination fight will drag out for at least another divisive week as a couple of Republican senators cave in supporting another FBI investigatio...
The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'
The satellite radio operator's stock is declining after announcing the purchase of the streaming radio service.
Stock buyers are back after Thursdays selloff helped by Pandora's jump higher. Dell's disaster continues and China has a fat finger trade.
A growing and aging population ensures biotechs won't go out of style.
US stock futures are rising on strong earnings from DuPont and Coach, while Amarin gets a nod from the FDA - Debra Borchardt gives details.
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Be willing to chase this rally, even though it's disliked by so many market players.
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.